Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for japanese patients with rare bone marrow cancer

NCT ID NCT04446650

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called fedratinib in Japanese adults with a serious bone marrow disease called myelofibrosis. The goal is to see if the drug can shrink an enlarged spleen and control the disease. About 31 people will take part, and the study will check safety and the best dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MYELOFIBROSIS

Contacts and locations

Locations

  • Local Institution - 001

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Local Institution - 002

    Aomori, 030-8553, Japan

  • Local Institution - 003

    Shinjyuku-ku, 160-0023, Japan

  • Local Institution - 004

    Bunkyō City, 113-8677, Japan

  • Local Institution - 005

    Isehara City, Kanagawa, 259-1193, Japan

  • Local Institution - 006

    Chūō, Yamanashi, 409-3898, Japan

  • Local Institution - 007

    Shinagawa-ku, Tokyo, 141-8625, Japan

  • Local Institution - 008

    Shinjuku, 162-8666, Japan

  • Local Institution - 009

    Nagasaki, 8528511, Japan

  • Local Institution - 010

    Kamogawa, 296-8602, Japan

  • Local Institution - 011

    Ōsaka-sayama, 589-8511, Japan

  • Local Institution - 012

    Miyazaki, 889-1692, Japan

  • Local Institution - 013

    Maebashi, 371-8511, Japan

  • Local Institution - 014

    Sapporo, 003-0006, Japan

  • Local Institution - 015

    Fukuoka, 812-8582, Japan

  • Local Institution - 016

    Osaka, 545-8586, Japan

  • Local Institution - 017

    Kitakyushu, 806-8501, Japan

  • Local Institution - 018

    Hitachi, Ibaraki, 317-0077, Japan

  • Local Institution - 019

    Takamatsu, 760-0017, Japan

  • Local Institution - 020

    Kumamoto, 8628655, Japan

  • Local Institution - 021

    Suwa, Nagano, 392-8510, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.